This study is being done to find the effect of Dibenzyl Trisulphide (active ingredient in Guinea Hen Weed in combination in patients with stage four cancer of the breast, prostate, cervix and colon.
There have been many claims of the value of Guinea Hen weed in the treatment of different cancers. The preparation is readily available and used locally. The team proposes to validate the studies done on cancer cell lines by conducting a clinical trial to determine the clinical benefit in advanced and metastatic cancers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
104
20 mg once daily for 6 months
20 mg once daily for 6 months
20 mg once daily for 6 months
Faculty of Medial Sciences
Kingston, Jamaica
RECRUITINGProstate Cancer
50% change in the Prostate Specific Antigen Response (PSA)
Time frame: Every 8 weeks up to 52 weeks
Breast Cancer
Changes in size of the metastatic legions
Time frame: Every 8 weeks up to 52 weeks
Colon Cancer
50% change in the Carcinoembryonic Antigen (CEA)
Time frame: Every 8 weeks up to 52 weeks
Cervical Cancer
50% change in renal function (Renal output)
Time frame: Every 8 weeks up to 52 weeks
Haemoglobin Red Cell Test
Blood - haemoglobin red cell count grams/decilitre
Time frame: Every 8 weeks upto 52 weeks
Blood Platelets Tests
Blood; platelet count per microlitre
Time frame: Every 8 weeks upto 52 weeks
Blood urea Tests
Blood Urea Nitrogen
Time frame: Every 8 weeks upto 52 weeks
Blood Creatinine
Amount of creatinine in the blood
Time frame: Every 8 weeks upto 52 weeks
Blood Electrolytes
Amount of electrolytes in the blood
Time frame: Every 8 weeks upto 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
20 mg once daily for 6 months
20 mg once daily for 6 months
20 mg once daily for 6 months
20 mg once daily for 6 months
20 mg once daily for 6 months
Blood Calcium
Amount of calcium in the blood
Time frame: Every 8 weeks upto 52 weeks
Blood Phosphorus
Amount of phosphorus in the blood
Time frame: Every 8 weeks upto 52 weeks
Prothrombin Test
Blood prothrombin time (PT).
Time frame: Every 8 weeks upto 52 weeks
Partial Prothrombin Test
Partial thromboplastin time( PTT).
Time frame: Every 8 weeks upto 52 weeks
White Blood Cell Test
white cell count per microlitre
Time frame: every 8 weeks up to 52 weeks
Computed Tomography (CT) Scan
A pelvis baseline scan and level of metastases quantified by a single radiologist.
Time frame: Every 8 weeks up to 52 weeks
Nuclear bone scintigraphy
A bone scintigraphy or X-ray to show number and site of metastases noted
Time frame: every 8 weeks up to 52 weeks
Bilirubin Direct test
Bilirubin direct, mmol per litre
Time frame: Every 8 weeks up to 52 weeks
Bilirubin Indirect test
Bilirubin indirect mmol per litre
Time frame: Every 8 weeks up to 52 weeks
Alkaline Phosphate level test (ALP)
Amount of Alkaline Phosphate enzyme in blood units per litre
Time frame: Every 8 weeks up to 52 weeks
Aspartate Aminotransferase test
Level of the aspartate aminotransferase enzymes in the blood units per litre
Time frame: Every 8 weeks up to 52 weeks
Gamma-glutamyl transferase test
Level of the Gamma-glutamyl transferase units per litre
Time frame: Every 8 weeks up to 52 weeks
Lactate dehydrogenase test
Level of Lactate dehydrogenase units per litre
Time frame: Every 8 weeks up to 52 weeks
Respiration
Number of breaths per minute
Time frame: Every 8 weeks up to 52 weeks
Temperature measurement
Temperature; degrees centigrade
Time frame: Every 8 weeks up to 52 weeks
Pulse
Pulse-beats per minute
Time frame: Every 8 weeks up to 52 weeks
Cancer Survival Curves
Proportion of patients alive after administration of intervention
Time frame: Every 8 weeks up to 52 weeks